BRAF V600E突变型胃肠间质瘤的临床病理特征与预后分析

doi:10.3969/j.issn.1671-7171.2026.04.013

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1296 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinicopathological characteristics of patients with BRAF V600E mutant gastrointestinal stromal tumors (GISTs) and their impact on prognosis. 【Methods】 A retrospective analysis was conducted on the clinical data of 58 patients with BRAF V600E mutant GISTs (mutation group) and 92 patients with BRAF wild-type GISTs (wild-type group). Clinicopathological features and survival outcomes were compared between the two groups. Univariate analysis and Cox proportional hazards regression models were used to identify independent prognostic factors for GIST. 【Results】 Compared with the wild-type group, the mutation group had a higher proportion of patients aged ≥55 years, tumors larger than 5 cm, and advanced TNM stage (stage Ⅲ+Ⅳ) (all P<0.05). Survival analysis showed that the mean overall survival (OS) and disease-free survival (DFS) in the mutation group were significantly shorter than those in the wild-type group (P<0.05). Univariate Cox regression analysis indicated that age, tumor size, TNM stage, and BRAF V600E mutation were adverse prognostic factors for GIST. Multivariate Cox regression analysis further demonstrated that age, tumor size, TNM stage, and BRAF V600E mutation were independent risk factors for poor prognosis in GIST. 【Conclusion】 Patients with BRAF V600E mutant GISTs exhibit poorer clinicopathological features and prognosis. Age, tumor size, TNM stage, and BRAF V600E mutation are independent prognostic risk factors for GIST.

Key words： Gastrointestinal Neoplasms Mesothelioma Pathological Conditions, Signs and Symptoms Prognosis

Received: 08 September 2025

PACS:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GU Guomei

Cite this article:

GU Guomei. Clinicopathological Characteristics and Prognostic Analysis of BRAF V600E-Mutant Gastrointestinal Stromal Tumors[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(4): 573-576.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.04.013 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I4/573

[1] 吴琼,姜慧杰.胃肠道间质瘤影像学研究进展[J].放射学实践,2024,39(2):287-292.
[2] 赵全铭,杨满斗,胡义波,等. 胃肠道间质瘤药物治疗和耐药机制研究进展[J].中国临床药理学与治疗学,2024,29(1):82-89.
[3] 彭娟,罗显丽,范如雪,等. 基于增强CT影像组学预测胃肠道间质瘤危险度分级[J].中国医学影像学杂志,2024,32(9):908-913.
[4] 时姗姗,王璇,夏秋媛,等. BRAF V600E突变特异性抗体在胃肠道间质瘤中的应用[J].中华病理学杂志,2016,45(8):566-570.
[5] 彭炜惟,沙欢欢,方瑛,等. BRAF V600E突变转移性结直肠癌治疗进展[J].肿瘤研究与临床,2024,36(5):396-400.
[6] 孙鑫,张巍,程令刚,等. 甲状腺乳头状癌临床、多模态超声及病理学特征与BRAF V600E突变的相关性[J].中国医学影像技术,2024,40(5):730-734.
[7] 康雅清,柯艺龙,杨谢锋,等. 常规磁共振成像联合DWI及PWI预测多形性黄色星形细胞瘤的BRAF V600E基因的突变状态[J].临床放射学杂志,2023,42(4):538-543.
[8] 林文松,黄冠,林宝行. 甲状腺乳头状癌及其临床病理特征与BRAF蛋白表达、BRAF V600E基因突变之间的关系[J].吉林医学,2024,45(2):262-265.
[9] 杨淋,王玉波. BRAF V600E突变非小细胞肺癌患者全程管理的研究进展[J].重庆医学,2024,53(5):782-786.
[10] 陈凤姣,周子爽,姚永坤,等. 甲状腺穿刺物BRAF V600E突变检测联合细胞学诊断在诊断甲状腺癌中的意义[J].农垦医学,2023,45(2):97-100.
[11] 张洁,任红臻,郭艳英. 甲状腺乳头状癌患者BRAF V600E突变与术后TSH抑制治疗达标所需L-T4剂量的关系[J].山东医药,2022,62(32):37-40.
[12] 李成乾,许翔,邢宝迪,等. BRAF V600E突变与甲状腺乳头状癌临床病理特征的相关性[J].现代肿瘤医学,2022,30(19):3493-3497.
[13] 周瑞瑜,吴立强,罗以. BRAF V600E基因突变与甲状腺乳头状癌远处转移及预后的关系[J].肿瘤药学,2022,12(3):387-390.